سعر نيوبريشن 2مجم 20 قرص 2024

Neopression 2 mg film-coated tablets, pack of 20 (Marcyrl, Egypt): brexpiprazole atypical antipsychotic.

• Adjunctive treatment to antidepressants for major depressive disorder (MDD) in adults.Population: AdultsDailyMed (U.S. National Library of Medicine)
• Treatment of schizophrenia in adults and pediatric patients aged 13 years and older.Population: Adults and adolescents ≥13 yearsDailyMed (U.S. National Library of Medicine)
• Treatment of agitation associated with dementia due to Alzheimer's disease (not for as-needed use).Population: AdultsDailyMed (U.S. National Library of Medicine)

• Most common: weight increased, somnolence and akathisia (adjunctive MDD); weight increased (adult schizophrenia); extrapyramidal symptoms (adolescent schizophrenia).International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Known hypersensitivity to brexpiprazole or any component (reactions included rash, facial swelling, urticaria, anaphylaxis).International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Boxed warning: increased mortality in elderly patients with dementia-related psychosis; not approved for dementia-related psychosis without agitation due to Alzheimer's dementia.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Boxed warning: antidepressants increased suicidal thoughts and behaviors in pediatric and young adult patients; monitor closely.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Other warnings: cerebrovascular events in elderly dementia patients, neuroleptic malignant syndrome, tardive dyskinesia, metabolic changes (hyperglycemia, dyslipidemia, weight gain), compulsive behaviors, leukopenia/neutropenia/agranulocytosis, orthostatic hypotension, falls, seizures, dysphagia and cognitive/motor impairment.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Strong CYP3A4 inhibitorsIncrease brexpiprazole exposure; administer half the recommended dosage (a quarter with combined strong/moderate CYP2D6 and CYP3A4 inhibitors).DailyMed (U.S. National Library of Medicine)
• Strong CYP2D6 inhibitorsAdminister half the recommended dosage (except adjunctive MDD use, where no adjustment is needed per label).DailyMed (U.S. National Library of Medicine)
• Strong CYP3A4 inducersDecrease brexpiprazole exposure; double the recommended dosage and adjust by response.DailyMed (U.S. National Library of Medicine)

• No adequate human studies; no teratogenicity in rats/rabbits at up to 73 and 146 times the MRHD. A pregnancy exposure registry exists.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• No human lactation data; brexpiprazole is present in rat milk. Weigh breastfeeding benefits against maternal need and potential infant effects.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Brexpiprazole: Mechanism unclear; efficacy may be mediated by partial agonism at 5-HT1A and D2 receptors and antagonism at 5-HT2A receptors (US label).